The short version of blood-brain barrier fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-26 and is reviewed periodically as new material appears.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
=== DSM-5 === The fifth edition of the DSM uses the term substance use disorder to refer to a spectrum of drug use-related disorders. The DSM‑5 eliminates the terms abuse and dependence from diagnostic categories, instead using the specifiers of mild, moderate, and severe to indicate the extent of disordered use. The number of diagnostic criteria present in a given case determines these specifiers. In the DSM‑5, the term drug addiction is synonymous with severe substance use disorder. The DSM‑5 introduced a new diagnostic category for behavioral addictions. Problem gambling is the only condition included in this category in the fifth edition. Internet gaming disorder is listed as a "condition requiring further study" in the DSM‑5. Past editions have used physical dependence and the associated withdrawal syndrome to identify an addictive state. Physical dependence occurs when the body has adjusted by incorporating the substance into its "normal" functioning – i.e., attains homeostasis – and therefore physical withdrawal symptoms occur on cessation of use. Tolerance is the process of the body adapting to a substance so that larger amounts are needed for the same effect. Withdrawal describes the physical and psychological symptoms that appear when a substance the body has adapted to is reduced or stopped. Which symptoms occur, and how dangerous they are, depends heavily on the substance: withdrawal from alcohol or benzodiazepines can be life-threatening, whereas withdrawal from most other substances is distressing but not usually dangerous.
=== Impact upon beta cells === Because it selectively kills the insulin-producing beta-cells found in the pancreas, alloxan is used to induce diabetes in laboratory animals. This occurs most likely because of selective uptake of the compound due to its structural similarity to glucose as well as the beta-cell's highly efficient uptake mechanism (GLUT2). In addition, alloxan has a high affinity to SH-containing cellular compounds and, as a result, reduces glutathione content. Furthermore, alloxan inhibits glucokinase, a SH-containing protein essential for insulin secretion induced by glucose. Most studies have shown that alloxan is not toxic to the human beta-cell, even in very high doses, probably because of differing glucose uptake mechanisms in humans and rodents. Alloxan is, however, toxic to the liver and the kidneys in high doses, as these are tissues where the GLUT2 transporter is expressed in humans.
Some non-α-amino acids exist in organisms. In these structures, the amine group is displaced further from the carboxylic acid end of the amino acid molecule. Thus a β-amino acid has the amine group bonded to the second carbon away, and a γ-amino acid has it on the third. Examples include β-alanine, GABA, and δ-aminolevulinic acid.
Figure 3 shows B versus R∗ for the rough pipe data of Nikuradse, Shockling, and Langelandsvik. In this view, the data at different roughness ratio ε/D fall together when plotted against R∗, demonstrating scaling in the variable R∗. The following features are present:
) within a single experiment. It consists of two cells which are enclosed in an adiabatic jacket. The compounds to be studied are placed in the sample cell, while the other cell, the reference cell, is used as a control and contains the buffer in which the sample is dissolved. The technique quantifies the heat released or absorbed during the binding process by incrementally adding one reactant (via a syringe) to another (in the sample cell) while maintaining constant temperature and pressure. Heat-sensing devices within the ITC detect temperature variations between two cells, transmitting this information to heaters that adjust accordingly to restore thermal equilibrium between the cells. This energy is converted into binding enthalpy using the information about concentrations of the reactants and the cell volume. Compared to other calorimeters, ITC does not require any correctors since there is no heat exchange between the system and the environment. ITC is also highly sensitive with a fast response time and benefits from modest sample requirements. While differential scanning calorimetry (DSC) can also provide direct information about the thermodynamic of binding interactions, ITC offers the added capability of quantifying the thermodynamics of metal ion binding to proteins.
Sources: en.wikipedia.org
Cold agglutinin disease (CAD) is a rare autoimmune disease characterized by the presence of high concentrations of circulating cold sensitive antibodies, usually IgM and autoantibodies that are also active at temperatures below 30 °C (86 °F), directed against red blood cells, causing them to agglutinate and undergo lysis. It is a form of autoimmune hemolytic anemia, specifically one in which antibodies bind red blood cells only at low body temperatures, typically 28–31 °C. When affected people's blood is exposed to cold temperatures (32 °F (0 °C; 273 K) to 50 °F (10 °C; 283 K)), certain proteins that normally attack bacteria (IgM antibodies) attach themselves to red blood cells and bind them together into clumps (agglutination). This eventually causes red blood cells to be prematurely destroyed (hemolysis) leading to anemia and other associated signs and symptoms. Cold agglutinin disease can be primary (unknown cause) or secondary, due to an underlying condition such as an infection, another autoimmune disease, or certain cancers. Treatment depends on many factors including the severity of the condition, the signs and symptoms present in each person, and the underlying cause. Cold agglutinin disease was first described in 1957.
=== Metasoma === The metasoma (the "abdomen") of the ant houses important internal organs, including those of the reproductive, respiratory (tracheae), and excretory systems. Workers of many species have their egg-laying structures modified into stings that are used for subduing prey and defending their nests.
Sjögren's disease may be excluded in people with past head and neck radiation therapy, active hepatitis C confirmed with a positive PCR test, acquired immunodeficiency syndrome, sarcoidosis, amyloidosis, graft-versus-host disease, and IgG4-related disease. Patients using anticholinergic drugs must stop using them for some time before being evaluated for symptoms of dryness.
The 43-second "Iron Gland" was developed out of a guitar riff that Cantrell would play that annoyed the other band members, so he created the song (adding in a reference to Black Sabbath's "Iron Man") and promised to never play the guitar riff again. It features Tom Araya of thrash metal band Slayer on vocals, as well as Layne Staley. "Hate to Feel" and "Angry Chair" were both composed solely by Staley, who also played guitar on both tracks, and Cantrell has expressed his pride in seeing Staley grow as a songwriter and guitarist. "Down in a Hole" was written by Cantrell to his long-time girlfriend, Courtney Clarke. Cantrell explained the song in the liner notes of 1999's Music Bank box set: "["Down in a Hole"]'s in my top three, personally. It's to my long-time love. It's the reality of my life, the path I've chosen and in a weird way it kind of foretold where we are right now. It's hard for us to both understand... that this life is not conducive to much success with long-term relationships." The album's final track, "Would?", was written by Cantrell as a tribute to his friend and late lead singer of Mother Love Bone, Andrew Wood, who died of a drug overdose in 1990. Cantrell said the song is also "directed towards people who pass judgments."
== External links == Overview of all the structural information available in the PDB for UniProt: P05305 (Endothelin-1) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
The patient is immunocompromised (for example, in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not responded to first line antibiotics; The disease might be dangerous to other patients, and the patient might have to be isolated
==== Saddam Hussein ==== In July 2007, the New Statesman printed selected portions of a 1976 piece by Hitchens which they claimed "took a more admiring view of the Iraqi dictator" than his later strong support for ousting Saddam Hussein. In this Hitchens pointed to Iraq's military strength, oil reserves and young leadership to argue that Iraq was "a force to be reckoned with" and described Saddam Hussein as a leader "who has sprung from being an underground revolutionary gunman to perhaps the first visionary Arab statesman since Nasser." He also argued:
==== E. Nerves of the nose ==== The sensations registered by the human nose derive from the first two branches of cranial nerve V, the trigeminal nerve. The nerve listings indicate the respective innervation (sensory distribution) of the trigeminal nerve branches within the nose, the face, and the upper jaw (maxilla).
=== Timeline === Mixue Ice Cream & Tea began in 1997 when Zhang Hongchao opened the first location under the Mixue name. After six relocations, the first successful Mixue Ice Cream & Tea store opened in 2003. Around 2005 or 2006, the company introduced soft serve ice cream at the price of just CN¥1, this quickly became a best-seller and its first signature product. In 2007, Mixue began franchising after opening a new ice cream shop. The following year, it established Mixue Ice Cream & Tea Trading Co., Ltd. to manage its growing network of franchises. Mixue took its first step outside of China on September 5, 2018, with a store opening in Hanoi, Vietnam. Later that year, in November, it launched a new brand mascot, Snow King. Between May 24 and 26, 2019, the company hosted an "ice cream music festival" at Opalala Water Park in Zhengzhou, drawing over 30,000 visitors. On June 24, 2020, Mixue celebrated the opening of its 10,000th store in Yuanyang County, Henan, Xinxiang. The same year, it expanded into Indonesia with a branch in Cihampelas Walk, Bandung. In 2022, Mixue made significant purchases of over 9,000 tonnes (8,900 long tons; 9,900 short tons) of tea, benefiting around 50,000 tea farmers, while also supporting over 11,000 franchisees and generating more than 500,000 jobs. It launched a CN¥6.5 million scholarship program across five universities in Henan and expanded into additional Southeast Asian markets, opening stores in Singapore, Thailand, Cambodia, Philippines, Laos, and Myanmar. By the end of 2022, Mixue had also entered South Korea and Japan.
Counterfeiting money is another financial crime. The counterfeiting of money includes illegally producing money that is then used to pay for anything desired. In addition to being a financial crime, counterfeiting also involves manufacturing or distributing goods under assumed names. Counterfeiters benefit because consumers believe they are buying goods from companies that they trust, when in reality they are buying low quality counterfeit goods. In 2007, the OECD reported the scope of counterfeit products to include food, pharmaceuticals, pesticides, electrical components, tobacco and even household cleaning products in addition to the usual films, music, literature, games and other electrical appliances, software and fashion. A number of qualitative changes in the trade of counterfeit products:
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.